Assessing the efficacy and safety for novel drug candidates for Alzheimer's disease requires a rigorous evaluation framework. Preclinical studies often involve in vitro and in vivo assays to assess its potential effectiveness in targeting disease-related pathways. Once promising candidates emerge, they progress through clinical trials that are con